News (135)

Transcript : Atea Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update AQ
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 AQ
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients AQ
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 AQ
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference AQ
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 AQ
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update AQ
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 AQ
Transcript : Atea Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update AQ
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination AQ
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference AQ
Transcript : Atea Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 08, 2023
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update AQ
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19 AQ
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases AQ
Atea Pharmaceuticals : Low Risk of Drug-Drug Interactions (DDIs) for Bemnifosbuvir (BEM) Based Upon In Vitro Metabolism and Transporter Interaction Studies PU
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research AQ
Transcript : Atea Pharmaceuticals, Inc., Q4 2022 Earnings Call, Feb 28, 2023
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update AQ
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023 AQ
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 03:00 PM
Atea Pharmaceuticals Highlights Strategic Priorities for 2023 AQ
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference AQ
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19 AQ
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference AQ
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference AQ
Transcript : Atea Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 07, 2022
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update AQ
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting AQ
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 12:55 PM
Transcript : Atea Pharmaceuticals, Inc. - Special Call
Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 AQ
Atea Pharmaceuticals Announces Upcoming Investor Events AQ
Atea Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K PU
Transcript : Atea Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 08, 2022
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update AQ
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference AQ
1234NextSee all

Companies (95)

AHLERS AG 156 147 $
Logo Ahlers AG

Ahlers AG is a Germany-based manufacturer of fashion products. It operates through two segments: Premium Brands and Jeans, Casual & Workwear. The Premium Brands segment comprises the Baldessarini, Pierre Cardin and Otto Kern brands, and provides clothes f ...

GASTEM INC. 8 978 $
Logo Gastem Inc.

Gastem Inc. is a Canada-based independent oil and gas exploration and development company. The Company has exploration properties rights and interests located in the Saint Lawrence Lowlands, the Gaspe Peninsula and the Magdalen Islands in Quebec. Its Magd ...

METRO INC. 12 303 M $
Logo Metro Inc.

Metro Inc. is a food and pharmacy retailers and distributors company. The Company, through its activities as a retailer, franchisor or distributor, and manufacturer operates or supplies a network of supermarkets, discount stores and drugstores. It operate ...

LEVI STRAUSS & CO. 8 836 M $
Logo Levi Strauss & Co.

Levi Strauss & Co. is an apparel company. The Company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's, Signatureby Levi Strauss & Co., Denizen, Dockers and Beyond Yoga brands. The Company operate ...

VIVAA TRADECOM LIMITED 2 M $
Logo Vivaa Tradecom Limited

Vivaa Tradecom Limited is an India-based company. The Company is engaged in the manufacturing as well as trading of cloths and garments. It is focused on selling readymade garments to various clients on a pan-India basis. Denim jeans garments and denim cl ...

SAINT JEAN GROUPE 74 M $
Logo Saint Jean Groupe

Saint Jean Groupe is an agri-food company and owning, at the end of 2023, 100% of Saint Jean (production of raviolis, dumplings, fresh pasta and catered products under the Saint-Jean, Royans, Ravioles de Romans, Quenelles La Royale and Comptoir du Pastier ...

GO METALS CORP. 2 M $
Logo Go Metals Corp.

Go Metals Corp. is a Canada-based exploration stage company. The HSP Nickel-Copper-Cobalt Project is located approximately 130 kilometers (km) north of Havre-Saint-Pierre in Quebec and approximately 150 square kilometers property is located within the Gre ...

PIERRE & VACANCES 746 M $
Logo Pierre & Vacances

Pierre & Vacances is a leading European operator of tourist residences and villages. Net sales break down by a ctivity as follows: - operation of residences and villages (94.5%): manages, at the end of September 2023, a total of 45,866 apartments and ho ...

RIGHT ON CO., LTD. 72 M $
Logo RIGHT ON Co., Ltd.

RIGHT ON Co.,Ltd. is a Japan-based company engaged in the operation of Jeans store. The Company offers casual wear which takes jeans as the core to a broad range of customers beyond age and gender. It also expands chain stores to the entire country, such ...

BLUE HOLDINGS INC. 37 $
Logo Blue Holdings Inc.

Blue Holdings, Inc. designs, manufactures and markets fashion jeans, apparel and accessories under the principal brand names Antik Denim, Taverniti So Jeans, Yanuk and Faith Connexion. The Company's products include jeans, jackets, belts, purses and T-shi ...


1234Next

Insiders

Picture Jean-Pierre Sommadossi
Jean-Pierre Sommadossi

Dr. Jean-Pierre Sommadossi is a Chairman at Kezar Life Sciences, Inc., a Chairman, President & Chief Executive Officer at Atea Pharmaceuticals, Inc., a Member-Discovery Council at Harvard Medical School and an Independent Director at ABG Acquisition Corp. I. He is on the Board of Directors at Rafael Pharmaceuticals, Inc., The BioExec Institute, Inc. and ABG Acquisition Corp. I. Dr. Sommadossi was previously employed as a Chairman, President & Chief Executive Officer by Idenix Pharmaceuticals LLC, a Co-Founder by Pharmasset, Inc., a Professor by The University of Alabama at Birmingham, a Fogarty Fellow by Medical College of Virginia, a Fogarty Fellow by National Cancer Institute, and an Advisor by Puretech Health LLC. He also served on the board at Alzheon, Inc. and Kinex Pharmaceuticals, Inc. He received his doctorate degree from the University of Marseille.


Picture Jean-Pierre Chauvin
Jean-Pierre Chauvin

Jean-Pierre Chauvin is currently a Director at Andean American Gold Corp.
and the President of Chauvin Engineering Ltd.
He previously served as President, CEO & Director at Patricia Mining Corp., Executive Chairman at Wesdome Gold Mines Ltd., and President & COO at Globestar Mining Corp.
He also held various director positions at Battle Mountain Canada Ltd., Guyana Goldfields, Inc., Crown Butte Resources Ltd., Cypherpunk Holdings, Inc., PC Gold, Inc., Plateau Energy Metals, Inc., The Mining Association of Canada, Ontario Mining Association, Lakeside Minerals Corp., and Lineage Grow Co. Ltd.
Additionally, he was the General Manager-Canadian Operations at Battle Mountain Gold Co. and holds an undergraduate degree from Queen's University.


Picture Jean-Pierre Soublière
Jean-Pierre Soublière

Jean-Pierre Soublière is Co-Chairman of Atomic Energy of Canada Ltd.
He is President of Anderson Soublière, Inc. Mr. Soublière is a Director of International DataCasting Corporation, Med-Eng Systems, Inc., Positron Public Safety Systems, Inc., and the Ottawa Health Research Institute.
Previously he was President and Chief Operating Officer of Alis Technologies from 1997 to 1999.
Mr. Soublière was President of SHL Systemhouse International.
He received a Bachelor's degree from the University of Ottawa in 1967 and an MBA from the University of British Columbia in 1971.


Picture Jean-Pierre Pelletier
Jean-Pierre Pelletier

Jean-Pierre Pelletier is currently a Director at Fortune Energy, Inc. (Canada), Raider Resources, Inc., New Forty-Four Mines Ltd., Portage Avenue Gold Mines Ltd., and Canadian Fortune Resources, Inc. He is also the Head of Operations & Human Resources at Qohash, Inc. since 2018.
Previously, he was an Independent Director at Tuktu Resources Ltd.
He graduated from Université Paris 8 Vincennes Saint-Denis in 1974.



Picture Jean-Pierre Guenin
Jean-Pierre Guenin

Mr. Jean-Pierre Guenin joined Innovacom in January 2001 as director of business development.
He is active in the development of revenue and affiliate relationships with France Telecom’s various operating entities (parent company and subsidiaries), both in France and abroad.
From 1994 to 2000 he served on the team that developed France Telecom’s Internet activity: the launch of Wanadoo and the creation and development of the VoiLa portal, both in France and abroad.
He previously held various positions within the France Telecom Group in the videophone and ISDN areas.
Before 1988, he managed a France Telecom R&D department in the field of data transmissions.
Mr. Guenin has a Ph.D in engineering, and is a graduate of the École Nationale Supérieure des Télécommunications




Picture Jean-Pierre Dick
Jean-Pierre Dick

Jean-Pierre Dick is currently the Chairman at Fondation d’Entreprise.
Virbac since 2013.
He is also a Member at Défi Voile Sud association, a Manager at Absolute Dreamer SARL since 2013, a Joint Manager at SCI Terre du Large, and a Co-Manager at Samakeur JP.
Previously, he worked at Virbac SA from 1996 to 2019 as a Member-Executive Board.
Dr. Dick holds an MBA and a doctorate from École des Hautes Études Commerciales de Paris.


No results for this search

  1. Stock Market
  2. Advanced search
  3. Jean-Pierre Sommadossi